Expert Discussed Long Term iFCR Therapy Follow Up for Younger Individuals With Chronic Lymphocytic Leukemia

Video

Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses what the results of the initial iFCR study showed and what the highlights of the longer-term follow up were for individuals with chronic lymphocytic leukemia.

In a Pharmacy Times® Interview, Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses his oral presentation at ASH 2021 of the Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic Leukemia (CLL).

He discussed what the results of the initial iFCR study showed and what the highlights of the longer-term follow up were.

Related Videos
Home Diabetes Treatment - Image credit: Dglimages | stock.adobe.com
Image credit: Azee/peopleimages.com | stock.adobe.com
Cropped view of senior man playing with puzzles on table- Image credit: LIGHTFIELD STUDIOS | stock.adobe.com
Breast cancer with lymphatics, medically 3D illustration | Image Credit: Axel Kock - stock.adobe.com
Woman with pink ribbon on color background. Breast cancer awareness concept | Image Credit: Pixel-Shot - stock.adobe.com
Pharmacy, medicine and senior woman consulting pharmacist on prescription. Healthcare, shopping and elderly female in consultation with medical worker for medication box, pills or product in store- Image credit: C Daniels/peopleimages.com | stock.adobe.com
View in microscopic of pathology cross section tissue ductal cell carcinoma or adenocarcinoma diagnosis by pathologist in laboratory | Image Credit: arcyto - stock.adobe.com
A female doctor sits at her desk and talks to a female patient while looking at her mammogram | Image Credit: lordn - stock.adobe.com
Doctor holding a digital tablet with x-ray of brain and skull skeleton. Headache, meningitis and migraine concept - Image credit: Steph photographies | stock.adobe.com
© 2023 MJH Life Sciences

All rights reserved.